


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (canceled)

Claim 2 (currently amended): A method of treating a patient infected with hepatitis B virus and HIV comprising administering to the patient a first compound of  $\beta$ -L-2-amino-6-(OH, Cl, NH<sub>2</sub>, or H)-9-[(4-hydroxymethyl)-tetrahydrofuran-1-yl]purine or a compound of structure (I), (II), or (III), or a pharmaceutically acceptable salt or prodrug thereof,



in combination with a second compound selected from:

- a) 3'-azido-3'-deoxythymidine (AZT),
- b) 2',3'-dideoxyinosine ((DDI),
- c) 2',3'-dideoxy-2',3'-didehydrothymidine (D4T),
- d) 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC),
- ~~e) 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (BCH-189),~~
- ~~f) e~~ a non-nucleoside RT-inhibitor, or
- ~~g) f~~ a physiologically acceptable salt or prodrug thereof,

wherein

- a) R<sup>1</sup> is hydrogen, fluoro, bromo, chloro, iodo, methyl or ethyl,
- b) R<sup>2</sup> is OH, Cl, NH<sub>2</sub>, or H,

- c)  $R^3$  is hydrogen;  $C_1$ - $C_{20}$  alkyl; acyl in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic  $C_1$ - $C_{20}$  alkyl, phenyl, or benzyl; a naturally occurring or nonnaturally occurring amino acid; alkoxyalkyl; aralkyl; aryloxyalkyl; aryl; a dicarboxylic acid; a sulfonate ester; or a mono, di or triphosphate ester, and
- d)  $R^4$  is hydrogen;  $C_1$ - $C_{20}$  alkyl; acyl in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic  $C_1$ - $C_{20}$  alkyl, phenyl, or benzyl; alkoxyalkyl; aralkyl; aryloxyalkyl; or aryl.


Claim 3 (currently amended):        The method of claim 1 2 wherein the first compound is administered in enantiomerically enriched form.

Claim 4 (currently amended):        The method of claim 1 2 wherein the first compound is defined by structure (I).


Claim 5 (currently amended):        The method of claim 1 2 wherein the first compound is defined by structure (II).

Claim 6 (currently amended):        The method of claim 1 2 wherein the first compound is defined by structure (III).


Claim 7 (currently amended):        The method of claim 1 wherein the first compound is defined by structure (IV)



Claim 8 (currently amended): The method of claim 1 wherein the first compound is defined by structure (V)



Claim 9 (previously presented): The method of claim 1 wherein the first compound is defined by structure (VI)



Claim 10 (currently amended): The method of claim 1 2 wherein the first compound is  $\beta$ -L-2',3'-dideoxycytidine ( $\beta$ -L-DDC) or a pharmaceutically acceptable salt or prodrug thereof.

Claim 11 (currently amended): The method of claim 1 2 wherein the first compound is  $\beta$ -L-2',3'-dideoxy-5-fluorocytidine ( $\beta$ -L-FddC) or a pharmaceutically acceptable salt or prodrug thereof.

Claim 12 (currently amended): The method of claim 1 2 wherein the first compound is  $\beta$ -L-2',3'-dideoxy-5-(halo)cytidine or a pharmaceutically acceptable salt or prodrug thereof.

Claim 13 (currently amended): The method of claim 1 2 wherein the first compound is  $\beta$ -L-2',3'-dideoxy-5-(methyl)cytidine or a pharmaceutically acceptable salt or prodrug thereof.

Claim 14 (currently amended): The method of claim 1 2 wherein the first compound is  $\beta$ -L-2-amino-6-(OH, Cl, NH<sub>2</sub>, or H)-9-[(4-hydroxymethyl)-tetrahydrofuran-1-yl]purine or a pharmaceutically acceptable salt or prodrug thereof.

Claim 15 (currently amended): The method of claim 1 2 wherein the first compound is  $\beta$ -D-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-dioxolane ( $\beta$ -D-FDOC) or a pharmaceutically acceptable salt or prodrug thereof.

Claim 16 (currently amended): A method of treating a patient infected with hepatitis B virus and HIV comprising administering to the patient  $\beta$ -L-2'-F-3'-deoxy-5-fluorocytidine (2'-F- $\beta$ -L-FddC) or a pharmaceutically acceptable salt or prodrug thereof, in combination with a second compound selected from:

- a) 3'-azido-3'-deoxythymidine AZT,
- b) 2',3'-dideoxyinosine (DDI),


- c) 2',3'-dideoxy-2',3'-didehydrothymidine (D4T),
- d) 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC),
- e) ~~2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (BCH-189),~~
- f) ~~e)~~ a non-nucleoside RT-inhibitor, or
- g) ~~f)~~ a physiologically acceptable salt or prodrug thereof.

Claim 17 (currently amended): A method of treating a patient infected with hepatitis B virus and HIV comprising administering to the patient  $\beta$ -L-2',3'-dideoxyadenosine ( $\beta$ -L-DDA) or a pharmaceutically acceptable salt or prodrug thereof, in combination with a second compound selected from:

- a) 3'-azido-3'-deoxythymidine (AZT),
- b) 2',3'-dideoxyinosine (DDI),
- c) 2',3'-dideoxy-2',3'-didehydrothymidine (D4T),
- d) 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC),
- e) ~~2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (BCH-189),~~
- f) ~~e)~~ a non-nucleoside RT-inhibitor, or
- g) ~~f)~~ a physiologically acceptable salt or prodrug thereof.

Claim 18 (previously presented): The method of claim 17 wherein the  $\beta$ -L-2',3'-dideoxyadenosine  $\beta$ -L-DDA is administered in enantiomerically enriched form.

Claim 19 (currently amended): A method of treating a patient infected with hepatitis B virus and HIV comprising administering to the patient a first compound of structure (VII), or a pharmaceutically acceptable salt or prodrug thereof,



in combination with a second compound selected from:

- a) 3'-azido-3'-deoxythymidine (AZT),

- b) 2',3'-dideoxyinosine (DDI),
  - c) 2',3'-dideoxy-2',3'-didehydrothymidine (D4T),
  - d) 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC),
  - e) ~~2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (BCH-189),~~
  - ~~f) e)~~ a non-nucleoside RT-inhibitor, or
  - ~~g) f)~~ a physiologically acceptable salt or prodrug thereof,
- wherein R<sup>5</sup> is a purine.

Claim 20 (previously presented): The method of claim 19 wherein the first compound is administered in enantiomerically enriched form.